Immunome Inc. income statement

In fiscal 2025, Immunome Inc. reported revenue of $6.9m, down 23.2% on the year before, operating income of −$224m (a -3228.8% margin) and net income of −$212m, or −$2.43 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Immunome Inc.: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	14	9	7	0
Research and development	23	130	177	206
General and administrative	20	33	44	54
Operating income	−110	−306	−224	−270
Net interest income	3	13	12	16
Income tax	0	0	0	—
Net income	−107	−293	−212	−254
Diluted EPS	−$1.79	−$5.00	−$2.43	−$2.48
Diluted shares (average)	60m	59m	87m	102m
EBITDA	−109	−304	−222	−268

US$ millions unless shown otherwise. Fiscal quarters.

Immunome Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	3	3	3	4	0	0	0	0
Research and development	37	48	37	40	49	51	46	60
General and administrative	10	10	11	10	11	12	13	18
Operating income	−51	−83	−45	−46	−60	−73	−59	−78
Net interest income	3	3	3	3	3	3	5	5
Net income	−47	−80	−42	−43	−57	−70	−54	−73
Diluted EPS	−$0.78	−$1.28	−$0.52	−$0.50	−$0.65	−$0.75	−$0.48	−$0.65
EBITDA	−50	−83	−44	−46	−60	−72	−59	−77

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immunome Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immunome Inc.